At Platinum Discovery our scientists have access to state-of-the-art laboratory instrumentation and facilities for modern ‘omics’ research and data analysis. Our partnerships with leading academic researchers and clinical scientists, enables the Platinum Discovery team to design projects and research teams tailored to the specific needs of each individual client.
Our vision is to help our clients drive scientific breakthroughs in advanced therapeutics and diagnostics development. We advance your research by bringing proven expertise and access to modern laboratory and data technologies, driving efficiency in every step of your discovery pipeline. Platinum Discovery will help you to identify new drug targets, biomarkers and therapeutics by designing and delivering programmes that optimise research outcomes.
Platinum Discovery have a wealth of experience in the design and management of complex research programmes. We assemble expert teams specifically for each client programme. We draw on our access to expert staff, consultants and advisers to ensure we build teams with the best combination of cell and molecular laboratory skills, access to clinical expertise, instrumentation and services, including advanced informatics skills and our proprietary software tools.
A unique advantage is our access to an established network of expert partners, including the School of Life Sciences at the University of Dundee, a world-class academic institution with a reputation for excellence in research.
Angus is a world leading biochemist specialising in quantitative analyses of gene expression in human cells and model organisms. He is a Co-Founder and Chief Scientific Officer of Platinum Informatics. The Lamond Laboratory research how the expression of genes is controlled in human cells and it was in the Lamond Laboratory that Platinum Informatics was born. A Professor of Biochemistry at the University of Dundee since 1995, Angus has authored over 250 peer reviewed publications in major scientific journals. Angus is a distinguished speaker who is regularly invited to present his work at international conferences and seminars. He has served on numerous national and international review committees and scientific advisory boards and chaired important funding and appointment committees. After graduating with a degree in Molecular Biology from the University of Glasgow, Angus obtained his PhD in Cambridge at the MRC Laboratory of Molecular Biology and was awarded a Junior Research Fellowship at Christ’s College. Angus next moved to the USA as a postdoctoral fellow, working at M.I.T. with the Nobel Prize Winner Phillip Sharp, where he studied the mechanism of pre-mRNA splicing in mammalian cells. He then moved to Germany, where he worked for 8 years as a Group Leader at the European Molecular Biology Laboratory in Heidelberg. In Heidelberg, while Angus continued to study the mechanism of pre-mRNA splicing in human cells, he also started using mass spectrometry-based proteomics methods to analyse gene expression. Angus has 30 years’ experience in directing a multidisciplinary life sciences research laboratory, combining molecular cell biology with mass spectrometry and computational approaches, where he was an early adopter of ‘Big Data’ technologies. His research techniques have uncovered regulatory pathways that affect gene expression in the context of both health and disease, with a major current focus on studying human stem cells.
Mukesh is a strategic commercial leader specialising in the sales and marketing of high technology medical devices and diagnostics systems in international healthcare markets. With a 22-year track record of on-target delivery for an array of products at different stages in their life-cycles, Mukesh brings a wealth of strategic insight and leadership to the role of Chief Executive Officer at Platinum Informatics. A chartered marketeer and lawyer, Mukesh joined Johnson and Johnson in 1996. After a successful period in sales, he quickly became involved in start-up medical device design and market assessment for product concepts. In 2000 he moved to a European role based in Hamburg, Germany, joining the licensing and acquisition group, before becoming Pricing Director for Europe in 2002. He continued his development with Johnson & Johnson taking on leadership roles in the UK and became a member of the leadership team for Ethicon Endo-Surgery, part of the family of J&J companies, holding the positions of Commercial Director, Marketing Director and Sales Director. During this time, the business grew at strong double-digit growth, whilst achieving substantial operational efficiencies. An accomplished and passionate marketeer, Mukesh subsequently spent ten years in senior EMEA marketing and market access leadership roles. During this time, he oversaw the launch of significant products in both medical devices and diagnostics, as well as, helping to create a new product launch process that positively disrupted a long-established market. Mukesh has in-depth knowledge of the acquisition and integration of newly acquired companies and has helped develop emerging market strategies for Russia and the Middle East. He was part of a leadership team who turned around a declining in vitro diagnostic portfolio to achieve double-digit growth success. Putting integrity, the customer and talent development at the heart of the culture he creates is key to the achievements Mukesh has orchestrated throughout his career.
Ken has 40 years’ experience of the life sciences sector accumulated through working in the pharmaceutical industry in sales and marketing roles, in investment research of the sector and related corporate finance, and as a member of the management group at PA Consulting Group. At PA his activities emphasised business strategy, new product development and commercialisation, business performance improvement and organisational development. At PA Ken worked across the range of companies in the sector – Big Pharma, SMEs / Specialists and start-ups. Most recently Ken has worked independently as a consultant, collaborated with several providers of specialist services to the life sciences sector, and has joined the boards of start-up life sciences companies where his capabilities and experience have provided support to the management teams as they develop their strategies and crucially engage with new investors to secure the funds required to progress their businesses.